Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemagglutinin-strain a(h1n1)
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Haemagglutinin-strain A(H1N1) is the hemagglutinin protein derived from the influenza A virus subtype H1N1. It is used as an active component in various inactivated influenza vaccines. Hemagglutinin (HA) is a surface glycoprotein of the influenza virus responsible for binding to host cell receptors containing sialic acid and mediating fusion between viral and endosomal membranes during infection initiation. The HA protein is highly immunogenic and serves as the primary antigen targeted by neutralizing antibodies following vaccination or natural infection. Vaccines containing this antigen are indicated for prevention of influenza caused by H1N1 strains[3][4][5][8]. The mechanism of action involves induction of an immune response against HA to prevent viral entry into host cells.
- Brand names
- afluira tetraagrifluflulaval tetrafluadfluad pediatricfluviralfluzonefluzone high-dose quadrivalentfluzone quadrivalentinfluvac tetra
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on haemagglutinin-strain a(h1n1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemagglutinin-strain a(h1n1).